Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28222973 | 0.88 | NPC1 (0.49) | MAPTHTR6CYP19A1CES1SIGMAR1 | |
| SCHEMBL16738816 | 0.83 | ACHE (0.49) | MAPTHTR6CYP19A1CES1KDM4E | |
| SCHEMBL29521877 | 0.80 | CES1 (0.47) | MAPTCYP19A1CES1KDM4ESIGMAR1 | |
| SCHEMBL10583071 | 0.80 | CES1 (0.47) | MAPTHTR6CYP19A1CES1KDM4E | |
| SCHEMBL10399251 | 0.80 | CES1 (0.47) | MAPTCYP19A1CES1KDM4ESIGMAR1 | |
| SCHEMBL29924839 | 0.80 | CYP26A1 (0.47) | MAPTHTR6SIGMAR1ACHEDRD2 | |
| SCHEMBL27772918 | 0.79 | KDM4E (0.46) | MAPTCYP19A1CES1KDM4ESIGMAR1 | |
| SCHEMBL11784556 | 0.78 | HTR6 (0.77) | MAPTHTR6KDM4ESIGMAR1AKR1C3 | |
| SCHEMBL21060838 | 0.73 | MAPT (0.63) | MAPTHTR6KDM4EACHEHTR2A | |
| SCHEMBL314549 | 0.73 | HTR6 (0.40) | MAPTHTR6KDM4EAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8889906-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
| US-8093424-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-7981923-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| EP-1831152-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| EP-1831159-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | disclosed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | disclosed |
| US-20060154965-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006066790-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | MAPT 905/4885HTR6 1360/4885CYP19A1 66/4885 |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | MAPT 618/4885HTR6 1638/4885CYP19A1 36/4885 |
| US-20060154965-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | MAPT 618/4885HTR6 1638/4885CYP19A1 36/4885 |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | HTR2A, HTR1A, HTR5A | MAPT 2906/4885HTR6 7/4885CYP19A1 1402/4885 |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | MAPT 4183/4885HTR6 427/4885CYP19A1 89/4885 |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | CYP3A7, PARK7, IPO5 | MAPT 145/4885HTR6 939/4885CYP19A1 1105/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | MAPT 618/4885HTR6 1638/4885CYP19A1 36/4885 |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | MAPT 44/4885HTR6 829/4885CYP19A1 1443/4885 |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | MAPT 44/4885HTR6 829/4885CYP19A1 1443/4885 |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | MAPT 618/4885HTR6 1638/4885CYP19A1 36/4885 |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | MAPT 44/4885HTR6 829/4885CYP19A1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.